LYMPHOSIGN
LymphoSign is a pharmaceutical company that is focused on the development of drugs for blood cancers. LymphoSign was acquired by Aegera Therapeutics in August 2007. LymphoSign was founded in 2000 and is based in Markham, Canada.
LYMPHOSIGN
Industry:
Biotechnology Health Care Medical Medical Device
Founded:
2000-01-01
Address:
Markham, Ontario, Canada
Country:
Canada
Website Url:
http://www.lymphosign.com
Total Employee:
11+
Status:
Active
Contact:
(905) 530-2333
Total Funding:
5.9 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Google Tag Manager Google Universal Analytics Euro ReCAPTCHA
Similar Organizations
Integra LifeSciences
Integra LifeSciences is an integrated medical device company.
Investors List
GeneChem
GeneChem investment in Series A - LymphoSign
VenGrowth Asset Management
VenGrowth Asset Management investment in Series A - LymphoSign
Official Site Inspections
http://www.lymphosign.com Semrush global rank: 2.52 M Semrush visits lastest month: 6.97 K
- Host name: 104.21.96.1
- IP address: 104.21.96.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "LymphoSign"
LymphoSign Journal
Oct 23, 2024 · LymphoSign Journal Novel mutation and VUS 26 Feb 2021 A novel splice site variant in FOXN1 in a patient with abnormal newborn screening for severe combined …See details»
About the Journal - lymphosign.com
LymphoSign Journal publishes novel clinical, translational, and basic research in the fields of immunology, gastroenterology, neurology, dermatology, rheumatology, hematology, and …See details»
Immunodeficiency Canada – Immunodeficiency …
Immunodeficiency Canada provides patient support, education, and research for a cure for Primary Immunodeficiency (PI). Donate Now! Immunodeficiency Canada brings the ’10 Warning Signs that every parent should know’ to life …See details»
Resource Links & Documents – Immunodeficiency …
LymphoSign Journal is the official publication of Immunodeficiency Canada. The journal provides a forum for clinicians and scientists to discuss clinical …See details»
LymphoSign - Crunchbase Company Profile & Funding
LymphoSign is a pharmaceutical company that is focused on the development of drugs for blood cancers. LymphoSign was acquired by Aegera Therapeutics in August 2007. LymphoSign was …See details»
Instructions for authors - lymphosign.com
All authors are required to submit a completed and signed copyright transfer or license to publish form licensing rights to LymphoSign Journal LP. The Copyright Transfer or Licence to Publish …See details»
LPSN v005i004 Cover - Immunodeficiency
To submit, use the journal’s online submission system at http:// mc06.manuscriptcentral.com/lpsn. The Instructions to Authors are available at http://lymphosign.com/page/lpsn-authors. All cor …See details»
ISSN 2292-5945 (Online) | LymphoSign journal - The ISSN Portal
URL http://lymphosign.com/journal/lpsn. Google https://www.google.com/search?q=ISSN+%222292-5945%22. Bing …See details»
Lymphosign - Overview, News & Competitors | ZoomInfo.com
LymphoSign Inc. is a biopharmaceutical company developing novel proprietary therapeutics for the treatment cancer. The Company has developed a family of small molecules which target …See details»
LymphoSign Journal LLP | Research4Life R4L
We aim to improve teaching, research and policy-making in health, agriculture, the environment and other life, physical and social sciences.National universities, professional schools, …See details»
LymphoSign Journal – Immunodeficiency Canada
LymphoSign Journal publishes peer-reviewed original research articles, reviews, clinical trials, case reports, novel mutations, and imaging, as well as practice guidelines, algorithms, and …See details»
Abstract - American Society of Hematology
Nov 5, 2021 · We (Bobée et al, 2020) have recently described a new molecular classifier combining gene expression profiling of 137 genes and machine learning able to diagnose B …See details»
Establishing reference ranges for lymphocyte proliferation …
Feb 25, 2019 · In this study, we collected retrospective data of lymphocyte proliferation responses to PHA from 39 patients with SCID, 52 patients with CID, as well as 440 healthy controls. Our …See details»
LymphoSign Journal
To submit, use the journal’s online submission system at http:// mc06.manuscriptcentral.com/lpsn. The Instructions to Authors are available at http://lymphosign.com/page/lpsn-authors. All cor …See details»
Histamine, histamine receptors, and anti-histamines in the context …
Apr 24, 2019 · Here, we describe the roles of these histamine receptors and antihistamines in the human system, clinical applications, side effects, and novel concepts for the usage of …See details»
Dysregulated CARD11 Signaling in the Development of
Aug 5, 2020 · Here we describe how dysregulated CARD11 activity can promote lymphomagenesis through branched signaling pathways whose components and …See details»
Microbiota-immune interactions: from gut to brain - LymphoSign …
Jan 27, 2020 · Here we review the role of microbiota-immune interactions in the gut and the brain during homeostasis and disease and their impact on gut-brain communication, brain function, …See details»
Dysregulated CARD11 signaling in the development of diffuse …
DOI: 10.14785/lymphosign-2020-0006 Corpus ID: 225419153; Dysregulated CARD11 signaling in the development of diffuse large B cell lymphoma …See details»
Novel mutation and VUS - LymphoSign Journal
Jun 2, 2024 · We present a case of an 11-year-old female with HIGM syndrome caused by two novel variants of in the CD40 gene. Aim: To describe a case report of an eleven-year-old …See details»
Recommendations for COVID-19 Testing - lymphosign.com
Oct 23, 2024 · LymphoSign Journal Just-IN Electronic, Individual, (access for 1 year)See details»